Diamond Biofund Announces Changes in Investment Holdings, Fair Value, Net Asset Value Per Share, and Cash Balance

Diamond Biofund Inc. announced its monthly report for March. The holdings of most invested companies remained unchanged, but the total fair value decreased by NT$84,898 thousand due to stock price fluctuations, with StemCyte and Sinphar suffering the most significant drops. As of the end of March, the net asset value per share was NT$10.40, and the cash and cash equivalents balance stood at NT$2,733,439 thousand. The company noted that investments in biotech stocks are highly volatile due to R&D outcomes, which may result in negative operating revenue when fair value declines.